Histogenics Corp (NASDAQ:HSGX) was the target of a significant drop in short interest during the month of February. As of February 28th, there was short interest totalling 411,801 shares, a drop of 84.3% from the February 15th total of 2,631,096 shares. Currently, 0.8% of the company’s shares are sold short. Based on an average trading volume of 3,856,960 shares, the short-interest ratio is presently 0.1 days.

Histogenics stock opened at $0.12 on Thursday. The stock has a market capitalization of $7.52 million, a P/E ratio of -0.12 and a beta of 3.71. Histogenics has a 12-month low of $0.08 and a 12-month high of $3.35.

HSGX has been the topic of several recent research reports. HC Wainwright cut Histogenics to a “hold” rating in a report on Wednesday, January 2nd. Zacks Investment Research upgraded Histogenics from a “hold” rating to a “buy” rating and set a $0.25 price target on the stock in a report on Tuesday, January 15th. Finally, ValuEngine cut Histogenics from a “hold” rating to a “sell” rating in a report on Monday, December 17th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Histogenics currently has an average rating of “Buy” and a consensus price target of $2.44.

In related news, major shareholder Randal J. Kirk sold 998,204 shares of the firm’s stock in a transaction dated Tuesday, January 15th. The stock was sold at an average price of $0.16, for a total value of $159,712.64. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Randal J. Kirk sold 251,800 shares of the firm’s stock in a transaction dated Friday, January 11th. The shares were sold at an average price of $0.17, for a total value of $42,806.00. The disclosure for this sale can be found here. 19.70% of the stock is owned by company insiders.

A number of institutional investors have recently bought and sold shares of the stock. BlackRock Inc. boosted its holdings in Histogenics by 72.0% in the second quarter. BlackRock Inc. now owns 54,753 shares of the biotechnology company’s stock valued at $137,000 after acquiring an additional 22,927 shares during the last quarter. Virtu Financial LLC bought a new position in Histogenics during the third quarter worth about $117,000. Finally, Geode Capital Management LLC bought a new position in Histogenics during the fourth quarter worth about $25,000. Institutional investors and hedge funds own 17.03% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.thecerbatgem.com/2019/03/14/short-interest-in-histogenics-corp-hsgx-declines-by-84-3.html.

About Histogenics

Histogenics Corporation, a clinical-stage company, focuses on the development of restorative cell therapies in the United States. The company offers NeoCart, a tissue implant, which is in Phase III clinical trial to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.

Read More: Outstanding Shares and The Effect on Share Price

Receive News & Ratings for Histogenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics and related companies with MarketBeat.com's FREE daily email newsletter.